Assessing historical utilization and spend patterns, we forecast that increasing GLP-1 weight loss utilization by just 1% in an insured population would drive more than an additional $10 in costs PMPM.

Keep reading: bit.ly/3IVj9iq

Prime Therapeutics and Magellan Rx Management are set to attend the upcoming AMCP conference next week. Throughout the week, attendees can visit our booth, and learn about our eight managed care pharmacy research studies.

More about our research here: bit.ly/3xvurHZ

David Lassen, chief clinical officer at Prime/MRx, recently spoke at the inaugural BMO Obesity Summit about the future of weight-management care as it relates to GLP-1 weight-loss drugs.

Keep reading: bit.ly/3PTS6rG

Prime Therapeutics/Magellan Rx Special Investigations Unit continues to help pharmacies and health care leaders remain educated on schemes and risks to patients when it comes to a growing concern around counterfeit GLP-1s.

Here’s how: bit.ly/3VLLWxM

Marci J Chodroff, MD, FACP talks to Managed Healthcare about specialty drugs, working at Prime, and vertical integration.

You can read the full conversation starting on page 9 here: bit.ly/3xl0EBI

In this episode of Pharmacy Friends, the CEOs of Prime Therapeutics, Mostafa Kamal, and Capital Rx, A. J. Loiacono, share the story behind the strategic alliance between their organizations.

Read more and listen to the full episode here: bit.ly/3TGWvPU

Curious how GLP-1s work?

GLP-1s are taken orally or subcutaneously. ➡️ Insulin is released. ➡️ As a result, blood sugar and appetite are reduced.

See forecasted GLP-1 weight loss utilization figures in our latest clinical perspectives here: bit.ly/3IVj9iq

Our clinical news is your monthly source for drug information highlights and trending topics: bit.ly/3TWGFB1

Our Special Investigations Unit works to identify and prevent opportunities for health care fraud. Learn more about the latest health care schemes we’ll be covering this month as part of our April Fraud Focus here: bit.ly/3TH7iK3

Take a closer look at our March update of newly approved specialty and traditional drugs, new indications and recent generic launches: bit.ly/3VHTTUv

Pharmacy Friends is our podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future and most importantly, what it means to you.

Listen to past episodes here: bit.ly/3t7nriJ

It’s no surprise that the use of GLP-1s for weight loss has taken the health care industry by storm.

Discover our holistic, individualized strategy to deliver exceptional and differentiated solutions here: bit.ly/3IVj9iq

In honor of #WomensHistoryMonth , we are sharing a series of employee spotlights from Women + Allies (W+A) Employee Resource Group (ERG) members at Prime/MRx.

Ginger Todd, sales executives of employer market sales, is this week's spotlight.

2024 trends have arrived! Discover next-generation management strategies, and download your own copy here today! bit.ly/3TAUSDp

We are excited to be attending the SIIA Spring Forum this week. If you're also attending, look for Jerry Homstad.

Learn more about the event here: bit.ly/4assuKz

Find your place at Prime.

Join our team and help reimagine pharmacy management to provide the same care you would want for your loved ones.

Learn more about the opportunities with Prime: bit.ly/3i1CkbW

Through a new strategic alliance, Prime Therapeutics will be the only PBM — aside from Capital Rx — to use Capital Rx’s JUDI platform. medcitynews.com/2024/03/pharma…

Sotatercept is a fusion protein therapy used to treat pulmonary arterial hypertension in adults.

Read the full high-cost therapy analysis from our team here: bit.ly/3PoeqcP

In honor of #WomensHistoryMonth we are sharing a series of employee spotlights from Women + Allies (W+A) Employee Resource Group (ERG) members at Prime/MRx.

Rebecca Herman, appeals supervisor of medical pharmacy solutions clinical operations, is this week's spotlight.

CMS has models for negotiating outcome-based agreements for cell and gene therapies. “One solution is Magellan Rx’s Value Plus, which is designed specifically for value-based contracting in the Medicaid fee-for-service market.”

More from FormularyWatch: bit.ly/49Z13ba